Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech ...

Genethon & Eukarÿs enter strategic partnership to develop a breakthrough technology to reduce the biomanufacturing cost of gene therapies: Evry, France Friday, January 24, 2025, ...

Marvai LifeSciences has acquired assets and intellectual property from Molecular Assemblies at undisclosed terms. Marvai, a San Diego company, said Tuesday that the acquisition would expand the ...

The partners will adapt Eukarÿs' C3P3 engineered enzyme tech to work with adeno-associated virus vectors to boost biomanufacturing yields.

Northwestern Medicine scientists have uncovered new details explaining how poxviruses manipulate host cells to enhance their ...

SAN DIEGO - Maravai LifeSciences, Inc. (NASDAQ: MRVI), a $796 million market cap company known for supplying life science reagents and services, has announced the acquisition of intellectual property ...

Rising demand for precision medicine & groundbreaking innovations in RNA sequencing drive growth in oncology, drug discovery, & personalized therapies.

For 2025, Lonza expects strong performance in its CDMO business with CER sales growth approaching 20% and CORE EBITDA margin approaching 30%. Excluding Vacaville, which is expected to contribute ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Ramakrishnan, a distinguished structural biologist and Nobel Laureate in Chemistry (2009), is renowned for his groundbreaking ...

we obtain best-in-class tools for cell-free synthesis and amplification of plasmid DNA, a key building block in mRNA manufacturing.” He continued: “OriCiro’s technology strategically ...

Creative Peptides, a leading research peptide innovator, announces enhancing its peptide library construction and screening services, which have been upgraded to accelerate drug development across ...